# Chipscreen Biosciences

Source: https://onco.cc/companies/chipscreen/  
OnCo record `chipscreen` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Chipscreen discovered chidamide (tucidinostat), the first original epigenetic cancer drug from China, approved in 2014 and later in Japan.

## Summary

Chidamide (Epidaza) approved 2014 for T-cell lymphoma and 2019 for breast cancer; licensed to HUYA Bioscience (HBI-8000) with Japanese approval 2021 and to Meiji Seika; chiglitazar for diabetes. Founded by Xianping Lu, a returnee from US biotech, before China's regulatory reforms made originator research routine.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- Also known as: 微芯生物
- Tags: china
- HQ: Shenzhen
- Type: biotech
- Website: https://www.chipscreen.com/en/
- Ticker: 688321.SS

## Sources

- Official website: https://www.chipscreen.com/en/

## Connected records

- fronts: [Epigenetic & Transcriptional Therapy](https://onco.cc/fronts/epigenetics/)
- drugs: [Chiauranib](https://onco.cc/drugs/chiauranib/), [Tucidinostat (chidamide)](https://onco.cc/drugs/tucidinostat/)
- trials: [A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients](https://onco.cc/trials/nct06497985/), [Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer](https://onco.cc/trials/nct04921527/), [Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype](https://onco.cc/trials/nct06947967/)
- roadmaps: [Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome](https://onco.cc/roadmaps/epigenetics-roadmap/)
- companies: [HUYABIO International](https://onco.cc/companies/huyabio/)

---
JSON: https://onco.cc/api/v1/entities/chipscreen.json